SEROTONIN NOREPINEPHRINE INHIBITOR MARKET ANALYSIS

Regional Analysis

Global Serotonin Norepinephrine Inhibitor Market- Regional Insights

• North America: North America is expected to dominate the serotonin norepinephrine inhibitor market due to the high prevalence of depression and anxiety disorders in the region. The presence of major pharmaceutical companies, favorable government initiatives, and increasing awareness about mental health issues are expected to further drive the market growth in this region. Moreover, increasing prevalence of diabetes in the region is expected to drive the growth of global serotonin norepinephrine inhibitor market over the forecast period. For instance, in 2022, according to data published by Panorama of Diabetes in the Americas, it is estimated that globally, the age-standardized prevalence of raised fasting glucose/diabetes has nearly doubled over 30 years, from 4.7% in 1980 to 8.5% in 2014, which reflects an increase in the number of people living with diabetes from 108 Mn  to 422 Mn . In the Americas, the age-standardized prevalence of raised fasting blood glucose (≥7.0 mmol/L) is estimated as 8.3%, with only a small difference between men (8.5%) and women (8.1%).
• Europe: Europe is also expected to witness significant growth in the serotonin norepinephrine inhibitor market due to the increasing prevalence of depression and anxiety disorders and the presence of major pharmaceutical companies. Increasing mental health awareness campaign in the region is expected to further boost the market growth in this region. For instance, Mental Health Europe (MHE) announced its fourth edition of the European Mental Health Week from May 22, 2023 to May 28, 2023. The goal of this year’s Awareness Week was  to increase understanding and learning about mental health in our communities, schools, workplaces, and at home so that everyone can thrive and flourish at every stage of life.